anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
We will use online ads to recruit people who are shopping online for soda, and direct them to a two-stage online Qualtrics experiment. In the first stage (Part I), we will elicit subjects' nutritional literacy and self-control for resisting sugary drinks, following the methodology of Allcott et al. (2019). Allcott et al. (2019) show that these two measures explain 31% of sugary drinks consumption in a nationally-representative sample of approximately 20,000 households, after controlling for detailed demographic information and elicitations of "tastes" for various types of drinks. Additionally, Allcott et al. (2019) demonstrate how these measures can be used to provide an estimate of over-consumption of sugary drinks at the individual level. Consequently, the first stage allows us to obtain estimates of the internality.

A week later, we will recruit participants in the first stage to participate in the second stage of the experiment (Part II). We create a time delay to minimize the potential effect of the first-stage questions on the second-stage choices. In the second stage, we will first ask participants to select their three favorite sugary drinks from a list. We will then ask participants to make an initial set of choices between those drinks and sugar-free alternatives (e.g., Seagram's Ginger Ale versus 365 Ginger) at various relative prices. Specifically, we will elicit their willingness to pay using a multiple price list, as is standard in the behavioral economics literature, where consumers answer a series of questions about whether they would prefer to buy a sugar-sweetened beverage at price X or a sugar-free alternative at price Y. Choices will be incentive-compatible: for each consumer we will honor their choice in a randomly selected decision (i.e., we will purchase the chosen package of soft drinks for them plus award them any additional money associated with that choice).

Following an initial set of choices, we will ask subjects to choose again. In this second set of choices, we will randomize whether participants see the soft drink options paired with an information label. We will also randomize the types of labels, including: (i) an inflated nutrition label that draws attention to the differences in calories and sugar content, (ii) the stoplight warning label developed by Grummon, Hall, et al. (2019), and (iii) a graphic warning label developed by Donnelly et al. (2018). The control group will instead make the same choices without seeing any label. Leveraging the within-subject nature of design, we will then estimate how well-targeted each information label is by estimating how the subjects' internalities covary with their changes in the prices at which they are willing to buy soft drinks after seeing the information label.
The physical exercise program will consist of aerobic exercise, exercise to enhance balance and flexibility, muscle-strengthening activities involving major muscle groups, and finger-toe movements. Cognitive training targets the cognitive domains of episodic memory, executive function, attention, working memory, calculation, and visuospatial function. Cognitive training will be conducted using a tablet-based application. Participants will be advised to eat something according to the recommendation of the Mediterranean-DASH Intervention for Neurodegenerative Delay diet (MIND) diet. They will be educated about vascular risk factor management every 2 weeks. The purpose of the motivational enhancement program is to induce, maintain, and strengthen motivation, which is a psychological resource to help maintain dementia prevention activities. All intervention will be administered via tablet personal computer (PC) application at home.
BACKGROUND: Pelvic girdle pain (PGP) is common during and after pregnancy. It has been assumed that Scandinavian women report more PGP than women of other ethnicities. However, there are few population-based studies on ethnic differences and few with ethnicity as risk factor for PGP. The purposes of the present study were: To examine the prevalence of self-reported PGP through pregnancy and early postpartum in a multi-ethnic cohort. To investigate how ethnicity and patient characteristics were associated with risk of PGP during pregnancy and early postpartum. To investigate if clinical and personal factors obtained in gestation week (GW) 15 were associated with PGP in GW28 and postpartum week (PPW) 14.
METHODS: This study analyzed questionnaire data from 823 women from the Stork - Groruddalen mult-iethnic cohort study in Norway. Chi-square tests were used to investigate ethnic differences in prevalence of self-reported PGP, and logistic regression analyses to identify factors associated with self-reported PGP.
RESULTS: Women from South-Asia and Middle East reported 10-20% higher prevalence of self-reported PGP at all time points compared with Western women. Ethnicity was associated with PGP in GW15 and PPW14, adjusted for parity. Pain locations in pelvic area (PGP locations) in GW15, especially combined symphysis and posterior PGP, gave the highest risk (OR=7.4) for PGP in GW28 and in PPW14 (OR = 3.9). Being multiparous was a risk for PGP in PPW14 (OR=1.9).
CONCLUSIONS: Women of South Asian and Middle Eastern background had higher risk of self-reported PGP than Western women. Ethnicity was associated with PGP in GW15 and PPW14, after adjustments for parity. PGP locations in GW15 was the most prominent risk factor for PGP in GW28 and PPW14, whilst ethnicity was not significant in multivariable analyses.
Among women with breast cancer, hot flashes are a frequent, severe and bothersome symptom. For this group, hot flashes are negatively related to mood, affect, and daily activities and can compromise compliance with life-saving medications (e.g., tamoxifen). Over 60% of breast cancer survivors report hot flashes, with 59% stating they are extremely severe and 44% reporting them to be extremely bothersome. Unfortunately, limitations in our understanding of hot flash physiology limit clinicians' abilities to fully treat this symptom. Although the current non-hormonal treatment of choice for hot flashes after breast cancer targets the central serotonin system (e.g., paroxetine, venlafaxine), the role of serotonin in hot flashes has not been directly tested. Because the effectiveness of these agents has been based largely on improvement in subjective reporting of hot flashes, it is not clear whether benefits are due to physiological effects on hot flashes or due to improvements in mood or other related symptoms. In addition, these and other currently available treatments are not acceptable, appropriate, or effective for all women with breast cancer. Understanding the physiological mechanisms involved in hot flashes after breast cancer will enable us to develop more targeted behavioral and/or pharmacological therapies to be used in lieu of, or in addition to, currently available therapies so that we can eradicate hot flashes and improve the quality of life for women with breast cancer.

Results implicating direct effects of tryptophan and serotonin on objective hot flashes will help guide the development of improved interventions for alleviating hot flashes in women with breast cancer. These interventions may target the central serotonin system either behaviorally (e.g., diet) or pharmacologically (e.g., alternative drug therapeutics). If direct manipulation of tryptophan and serotonin does not affect hot flashes, these findings will be equally as useful in guiding future research on non-serotonin related etiologies and interventions. Findings from this study will ultimately be used to eradicate hot flashes as a frequent, severe and bothersome breast cancer treatment related condition, thereby, improving quality of life for all women with breast cancer.
Gold thioitamalic acid is prepared by reacting thioitamalic acid with a gold chloride or bromide or with an alkali metal gold chloride or bromide.  Also an aqueous solution of the monosodium salt of gold thioitamalic acid is prepared by reacting one mol. of sodium hydroxide with an aqueous solution of an equal molecular quantity of gold thioitamalic acid or by reacting equal molecular proportions of gold thioitamalic acid and the disodium salt of gold thioitamalic acid in an aqueous medium, or further by reacting one mol. of the disodium salt of gold thioitamalic acid with the equivalent weight of an acid stronger than gold thioitamalic acid in aqueous solution. The gold compounds have therapeutic value especially the monosodium salts when suspended in an assimilable oil (see Group III).  In examples: (1) gold thioitamalic acid is obtained by reacting an excess of thioitamalic acid with auric chloride in water.  It is stated that auric bromide or aurous chloride or bromide may also be used; (2) as in (1) except that potassium auric bromide is used; (3) the monosodium salt is obtained by mixing one mol. of the gold acid with one mol. of sodium hydroxide in water; (4) the disodium salt is obtained by adding two mols. of sodium hydroxide to an aqueous solution of one mol. of the gold acid and the monosodium salt may be prepared from the disodium salt by reacting it with the gold acid as above or by adding thereto an acid such as hydrochloric acid.  The Specification as open to inspection under Sect. 91 states that other alkali metal salts as well as alkaline earth metal salts, amine and alkanolamine salts of the acids may be prepared, e.g. those of ammonia, triethanolamine, monoethanolamine and methylglycamine, and both the mono- and di-amine salts are mentioned.  The calcium salt of the acid is also prepared by adding an excess of calcium chloride to an aqueous solution of the monosodium salt of the acid.  This subject-matter does not appear in the Specification as accepted.ALSO:An aqueous solution of the monosodium salt of gold thioitamalic acid (see Group IV(b)) in concentrations up to 20 per cent or a suspension of the salt in an assimiliable oil especially a vegetable oil such as sesame, peanut, olive, rape seed and cotton seed oils are suitable for therapeutic treatment by injection. The aqueous solution or oil suspension of the salt may be sterilized by the conventional methods, e.g. by autoclaving with steam.  The Specification as open to inspection under Sect. 91, states that an oil suspension of the calcium salt of the gold thioitamalic acid (see Group IV(b)) is also suitable for injection.  This subject-matter does not appear in the Specification as accepted.
The present invention relates to a method of preparing medicines using a single flexible bag with multiple chambers. Medicines are introduced into a first chamber of the flexible bag through a first port in a liquid state. The medicines are freeze-dried in the first chamber of the flexible bag to be provided as a freeze-dried medicine. The flexible bag includes a second chamber, and the first chamber and the second chamber can be separated through a breakable seal. The second chamber additionally includes a re-composition solution for re-compose the freeze-dried medicine in the first chamber. A user can apply pressure to the flexible bag and break the seal to mix the freeze-dried medicine and the re-composition solution and apply the medicine to a patient.
Risk Summary

Based on its mechanism of action [see Clinical Pharmacology (12.1)] and findings in animals, Bortezomib Injection can cause fetal harm when administered to a pregnant woman. There are no studies with the use of bortezomib in pregnant women to inform drug-associated risks. Bortezomib caused embryo-fetal lethality in rabbits at doses lower than the clinical dose (see Data). Advise pregnant women of the potential risk to the fetus.

Adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Data

Animal Data

Bortezomib was not teratogenic in nonclinical developmental toxicity studies in rats and rabbits at the highest dose tested (0.075 mg/kg; 0.5 mg/m2 in the rat and 0.05 mg/kg; 0.6 mg/m2 in the rabbit) when administered during organogenesis. These dosages are approximately 0.5 times the clinical dose of 1.3 mg/m2 based on body surface area.

Bortezomib caused embryo-fetal lethality in rabbits at doses lower than the clinical dose (approximately 0.5 times the clinical dose of 1.3 mg/m2 based on body surface area). Pregnant rabbits given bortezomib during organogenesis at a dose of 0.05 mg/kg (0.6 mg/m2) experienced significant postimplantation loss and decreased number of live fetuses. Live fetuses from these litters also showed significant decreases in fetal weight.
The utility model relates to a medicine packaging structure specifically is a bottled formulation of lentinan for injection. The utility model relates to a problem prepared of formulation of solving the lentinan extract product. Its technical scheme is, including a medicine carrying section of thick bamboo, is equipped with the baffle in a medicine carrying section of thick bamboo, and the baffle divide into lentinan district, solvent district with a medicine carrying section of thick bamboo, is equipped with the hole on the baffle, is equipped with interior magnet cover in solvent district one side, and magnet cover outside the outer end in lentinan district is equipped with the pulling -on piece outside on the magnet cover. Interior magnet cover is opposite pole relative placement with outer magnet cover, makes it keep the gravitation relation. When needs use the medicine, pull open outer magnet cover to the reverse side is place in the original place, and under the repulsion effect of two magnet, the internal magnet is pushed open, then rocks the cartridge case, mixes both. The utility model discloses can realize the ration of medicine and solvent and pack into, also make things convenient for medical personnel's use, directly improve treatment.
PURPOSE: A composition containing Phellinus baumii-derived polyphenol extract for preventing and treating inflammatory diseases is provided to ensure excellent inflammation. CONSTITUTION: A composition for preventing or treating inflammatory diseases contains Phellinus baumii-derived polyphenol extract as an active ingredient. A composition for preventing or treating inflammatory diseases contains active compounds of Phellinus baumii-derived styrylpyrones as an active ingredient. The active compound is isolated from the polyphenol extract. The active compounds include interfugin A, baumin-Pb211, davallialactone, hispidin, hypholomine B, phelligridin D, or inoscavin A. A food composition contains the polyphenol extract.
Disclosed herein are bacteria-based HIV MPER vaccine candidates, as well as bacteria-based candidates for other viruses and for bacteria. The HIV vaccine candidates express MPER-derived antigens on their surfaces using Gram autotransporters. The surface-expressed MPER antigens bind several different MPER-directed anti-HIV Broadly Neutralizing Monoclonal Antibodies. When the bacteria expressing the MPER-derived antigens on their surfaces are used to immunize mice they elicit the production of sera and vaginal wash material that bind the bacteria expressing the MPER antigens. At least one of the bacteria expressing MPER-derived antigens on their surfaces elicits the production of sera with anti-HIV neutralizing activity. Killed whole cell and live  Salmonella  expressing the MPER derived antigens on their surfaces constitute new approaches to HIV vaccine develop that is plausible and that could ultimately yield an inexpensive, globally appropriate candidate vaccine that could be rapidly produced and deployed largely using currently available technology.
The TCSD Study will identify disparities in transitions of stroke care and key factors associated with effective transitions of care through structured telephone interviews to evaluate medication adherence, healthy lifestyle, utilization of rehabilitation interventions and medical follow-up 30 days after hospital discharge to home and in-patient care rehabilitation in 2,400 participants across 12 comprehensive stroke centers (CSC) in Florida. A novel Transitions of Stroke Care Performance Index (TOSC PI) will be derived and validated. The primary outcomes are the TOSC PI and 90-day readmission. Other stroke outcomes include stroke disability, recurrence, cardiovascular events, and death at 3 months. Outcomes will be collected through telephone interviews and review of patient charts. Predictors of disparities in transition of care and outcomes will be evaluated using baseline in-hospital data during acute stroke hospitalization obtained from the Florida Stroke Registry and Social Determinants of Health obtained through novel data collected from publicly available records. Based on identified predictors of disparities in TOSC, we will develop and demonstrate feasibility of initiatives for interventions to reduce disparities in TOSC that target systems of care with a TOSC disparities dashboard, and health care providers with a training module for enhanced education and support at discharge and during follow-up. We will evaluate any temporal improvements in the TOSC Performance Index and outcomes before and after the interventions.
Fathers for Change treatment begins with individual-focused sessions followed by co-parenting focused sessions and ending with restorative parenting sessions. The areas of focus for each of the three phases of Fathers for Change are: 1) abstinence from SA and violence; 2) co-parenting; 3) parenting/father-child relationship. Treatment begins with motivational enhancement by focusing the role of men as fathers to their young children, child development and the impact of violence and SA on parenting, and the father's own childhood experiences of SA and violence to highlight the multigenerational nature of these problems. The program then focuses on skills training in the following areas: reducing automatic hostile cognitions and increasing emotion regulation skills, 2) communication and problem solving around co-parenting, and 3) restorative parenting.
When allocated to the WLCG, participants receive BITT after a 3 months waiting period. The WLCG receives no care during the treatment phase (one week) of the intervention group. Besides this week the WLCG can undergo every treatment including EMDR and TF-CBT during the 3 months waiting period.
FIELD: biotechnology.SUBSTANCE: device (options) and system for preparing cell populations, method for producing a prepared stem cell composition, and method for increasing CD105+cell number in bone marrow of a patient are proposed. In one option, the device contains a feeding plate for liquid intake, a base plate and several intermediate plate. Each intermediate plate contains a distributing channel and a collecting channel. In another option, the device contains the first lid, the second lid and an intermediate module. The intermediate module includes a frame, an inlet for the flow, a distributing channel, inlet holes, drain holes, a collecting channel, a vertical channel. The system contains a base, modular devices, each device includes a feeding plate, a base plate, intermediate plates, the first and the second tubes, a reservoir and a pump. The method for producing a composition includes cultivation of stem cells on substrate, and application of controlled shift voltage to stem cells. The method for increasing CD105+cell number includes injection to a patient of an effective number of mesenchymal stem cells containing the composition prepared by the above-mentioned method.EFFECT: inventions provide for control of mechanical impact on cells intended for conditioning using controlled application of shift voltage to cells.75 cl, 25 dwg, 1 tbl, 2 ex
Uveitis accounts for more than 10% of all cases of severe vision loss in developed countries, which makes it possibly the fourth leading cause of blindness in the United States. Cystoid macular edema (CME) is the most structural complication of uveitis, resulting in visual impairment and blindness. If left untreated or undertreated over a period of years, CME may result in permanent photoreceptor damage of the macula and loss of central vision. Further, CME may persist despite adequate control of the uveitis, and therefore, adjuvant therapy to specifically treat the CME may be required.

We propose to study whether a sustained steroid delivery system (Ozurdex, Allergan) can treat uveitic macular edema. Ozurdex has been proven to be effective for non-infectious posterior uveitis; and FDA approved for posterior uveitis. The sustained delivery of the steroid and local delivery modality makes it an ideal candidate to manage macular edema in uveitis.
A remote care system includes a care device and a control center. The care device is configured to provide a user to wear and includes an emergency trigger, a detection module, a positioner, a communication module, an audio transceiver module and a control unit. The emergency trigger generates an emergency signal when being triggered. The detection module is configured to detect a user state information of the user. The positioner is configured to detect a position of the user. The communication module is communicatively connected to the control center. The control unit generates an emergency notification according to the emergency signal and controls the communication module to transmit the emergency notification, the user state information and the position to the control center. The control center transmits a calling ask to the control unit through the communication module according to the emergency notification. The control unit controls the audio transceiver module to perform a calling procedure according to the calling ask to provide the user to talk with the control center.
Cardiac arrhythmias are a common cardiac condition that might lead to fatal outcomes. A better understanding of the molecular and cellular basis of arrhythmia mechanisms is necessary for the development of better treatment modalities. To aid these efforts, various mouse models have been developed for studying cardiac arrhythmias. Both genetic and surgical mouse models are commonly used to assess the incidence and mechanisms of arrhythmias. Since spontaneous arrhythmias are uncommon in healthy young mice, intracardiac programmed electrical stimulation (PES) can be performed to assess the susceptibility to pacing-induced arrhythmias and uncover the possible presence of a proarrhythmogenic substrate. This procedure is performed by positioning an octopolar catheter inside the right atrium and ventricle of the heart through the right jugular vein. PES can provide insights into atrial and ventricular electrical activity and reveal whether atrial and/or ventricular arrhythmias are present or can be induced. Here, we explain detailed procedures used to perform this technique, possible troubleshooting scenarios, and methods to interpret the results obtained. © 2024 Wiley Periodicals LLC. Basic Protocol: Programmed electrical stimulation in mice.
Patients receive androgen deprivation therapy comprising bicalutamide PO QD on days 1-28 and either goserelin acetate SC or leuprolide acetate IM every 1, 3, 4, 6, or 12 months. Patients also receive cixutumumab IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for 7 courses in the absence of disease progression or unacceptable toxicity.
The placebo will consist of maltodextrin and will appear identical to the Testofen capsules. The placebo will be administered as per the active treatment - 2 capsules once daily for 12 weeks.
At Time 2 (two weeks after baseline), participants will receive the PCPM-EFI. Participants in the PCPM-EFI condition will be offered the PERPM-EFI after all assessments have been completed at Time 3.